IDN-6556 Idun Pharmaceuticals Inc

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


IDN-6556 is a lead compound from a class of small-molecule caspase protease inhibitors, and is currently under development by Idun as a potential treatment for acute alcoholic and infectious hepatitis. In October 2003, a phase II trial of IDN-6556 began in 100 patients undergoing liver transplantation.

Original languageEnglish (US)
Pages (from-to)1198-1204
Number of pages7
JournalCurrent Opinion in Investigational Drugs
Issue number11
StatePublished - Nov 1 2004
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'IDN-6556 Idun Pharmaceuticals Inc'. Together they form a unique fingerprint.

Cite this